Patents by Inventor John Morphy

John Morphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOUNDS
    Publication number: 20240067614
    Abstract: The invention relates to compounds of formula (I): and related aspects.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 29, 2024
    Applicant: NRG Therapeutics Ltd.
    Inventors: Neil MILLER, Richard RUTTER, Jan KULAGOWSKI, Richard MORPHY, Tammy LADDUWAHETTY, John MACLEAN, Mustafa MOROGLU, Eric TALBOT, Michael ROWLEY
  • 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES
    Publication number: 20080064678
    Abstract: Disclosed herein are 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivative of formula I, or pharmaceutically acceptable salts or solvates thereof wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives according to the present invention and their use in therapy.
    Type: Application
    Filed: September 10, 2007
    Publication date: March 13, 2008
    Applicant: N.V. Organon
    Inventors: Jeffrey Letourneau, Jui-Hsiang Chan, Patrick Jokiel, Michael Ohlmeyer, Irina Neagu, Christopher Riviello, John Morphy, Susan Napier, Koc-Kan Ho
  • Compounds with medicinal effects due to interaction with the glucocorticoid receptor
    Publication number: 20070149577
    Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicants: N.V. Organon, Pharmacopeia Drug Discovery Inc.
    Inventors: Niall Hamilton, Simon Grove, Michael Kiczun, John Morphy, Brad Sherborne, Peter Littlewood, Angus Brown, Celia Kingsbury, Michael Ohlmeyer, Koc-Kan Ho, Steven Kultgen